Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults

BACKGROUND: In early 2020, developing vaccines was an urgent need for preventing COVID-19 from a contingency perspective. METHODS: S-268019-a is a recombinant protein-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising a modified recombinant spike protein a...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonoyama, Takuhiro, Iwata, Satoshi, Shinkai, Masaharu, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Hemmi, Takuya, Ainai, Akira, Nagata, Noriyo, Matsunaga, Nobuaki, Tada, Yukio, Homma, Tomoyuki, Omoto, Shinya, Yokokawa Shibata, Risa, Igarashi, Kenji, Suzuki, Tadaki, Hasegawa, Hideki, Ariyasu, Mari
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755034/
https://www.ncbi.nlm.nih.gov/pubmed/36572603
http://dx.doi.org/10.1016/j.vaccine.2022.12.025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755034/
https://www.ncbi.nlm.nih.gov/pubmed/36572603
http://dx.doi.org/10.1016/j.vaccine.2022.12.025

Ejemplares similares